Akari Therapeutics Plc ADR
AKTX
Akari Therapeutics Plc ADR is an oncology biotechnology company focused on developing antibody-drug conjugates designed to deliver cancer-killing payloads directly to tumor cells. The company’s current work centers on its ADC discovery platform, which combines targeted antibodies with novel RNA spliceosome-modulating payloads to create candidates aimed at solid tumors. Its lead program, AKTX-101, is a preclinical TROP2-targeted ADC being studied across multiple tumor types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, and prostate cancers. Akari Therapeutics also maintains a broader research focus on advanced therapies for autoimmune and inflammatory diseases. As an ADR issuer, Akari Therapeutics Plc provides investors access to its ordinary shares through a U.S.-traded depositary receipt structure while the company advances its biotechnology programs from its headquarters in Tampa, Florida.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$31M
▲ +12.6% YoY
Op. Margin
–
ROIC
-35.02%
▲ +16.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$11M
▲ +15.8% YoY
Op. Cash Flow (TTM)
-$11M
▲ +15.8% YoY
Net Debt
-$4M
Net Cash Position
Cash & Equiv.
$5M
Continue Research
Peers
Biotechnology · Pick stocks to compare with AKTX
Akari Therapeutics Plc ADR (AKTX) in three numbers
- Quality score
- 20/100
- Best check: share count change, -16.5%. Weakest: return on capital, -35.0%.
- Quality
Questions about Akari Therapeutics Plc ADR
Is Akari Therapeutics Plc ADR a high-quality business?
Akari Therapeutics Plc ADR scores 20 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is share count change at -16.5%, and its weakest is return on capital at -35.0%. The Quality tab shows every check against its target.
Does Akari Therapeutics Plc ADR (AKTX) pay a dividend?
No. Akari Therapeutics Plc ADR (AKTX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing AKTX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.